Accessibility Menu
Sonoma Pharmaceuticals Stock Quote

Sonoma Pharmaceuticals (NASDAQ: SNOA)

$3.68
(-5.4%)
-0.21
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.68
Daily Change
(-5.4%) $0.21
Day's Range
$3.68 - $3.84
Previous Close
$3.68
Open
$3.84
Beta
1.10
Volume
19,719
Average Volume
1,244,275
Market Cap
6.4M
Market Cap / Employee
$3.89M
52wk Range
$1.75 - $6.92
Revenue
-
Gross Margin
0.38%
Dividend Yield
N/A
EPS
-$2.46
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Sonoma Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
SNOA+29.12%-97.71%-53.01%-100%
S&P+15.06%+95.03%+14.29%+373%

Sonoma Pharmaceuticals Company Info

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Financial Health

General

Q2 2025YOY Change
Revenue$4.02M18.4%
Gross Profit$1.46M12.1%
Gross Margin36.46%-2.1%
Market Cap$4.67M41.1%
Market Cap / Employee$0.03M0.0%
Employees168-2.3%
Net Income-$1.24M-8.6%
EBITDA-$1.06M6.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$3.61M39.2%
Accounts Receivable$2.60M-19.9%
Inventory3.843.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.44M621.3%
Short Term Debt$0.24M-34.5%

Ratios

Q2 2025YOY Change
Return On Assets-25.15%5.7%
Return On Invested Capital-67.88%-3.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$2.12M-131.3%
Operating Free Cash Flow-$2.02M-120.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.590.670.731.0595.31%
Price to Sales0.230.280.250.3110.02%
Price to Tangible Book Value0.590.670.731.0595.31%
Price to Free Cash Flow TTM30.53-
Enterprise Value to EBITDA0.811.182.44-1.6428.88%
Free Cash Flow Yield3.3%-
Return on Equity-66.9%-64.8%-65.5%-78.7%5.46%
Total Debt$0.24M$0.12M$0.31M$0.68M60.71%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.